Pepgen (PEPG) closed at $4.36 on November 13, 2026, down 13.5% from the previous close, on volume of 5,667,207 shares (30-day average 5,310,491).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Call Spread | 20-Nov-265 : 6 C | 2,002 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
PepGen Prices $125 Million Public Offering of Common Stock
TipRanks (Thu, 12-Nov 5:36 PM ET)
PepGen prices $125M public offering at $5 per share
Seeking Alpha News (Thu, 12-Nov 3:53 AM ET)
PepGen Announces Pricing of $125 Million Public Offering
Business Wire (Wed, 11-Nov 10:22 PM ET)
PepGen launches $125M stock offering to support clinical development
Seeking Alpha News (Tue, 10-Nov 4:46 PM ET)
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
Business Wire (Tue, 10-Nov 4:23 PM ET)
PepGen climbs 100% as BofA upgrades on new mid-stage trial data for lead asset
Seeking Alpha News (Tue, 10-Nov 2:31 PM ET)
Why Is Penny Stock PepGen (PEPG) Up 114% Today?
TipRanks (Tue, 10-Nov 1:28 PM ET)
TipRanks (Tue, 10-Nov 11:01 AM ET)
Market Chameleon (Tue, 10-Nov 4:52 AM ET)
PepGen GAAP EPS of -$0.28 misses by $0.01
Seeking Alpha News (Tue, 10-Nov 8:43 AM ET)
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Pepgen trades on the NASDAQ stock market under the symbol PEPG.
As of November 13, 2026, PEPG stock price declined to $4.36 with 5,667,207 million shares trading.
PEPG has a beta of 0.55, meaning it tends to be less sensitive to market movements. PEPG has a correlation of 0.00 to the broad based SPY ETF.
PEPG has a market cap of $301.97 million. This is considered a Small Cap stock.
In the last 3 years, PEPG traded as high as $19.30 and as low as $.88.
The top ETF exchange traded funds that PEPG belongs to (by Net Assets): VTI, IBB, VXF, IWC, BUSM.
PEPG has underperformed the market in the last year with a return of -10.8%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PEPG shares. However, PEPG has outperformed the market in the last 3 month and 2 week periods, returning +46.3% and +84.7%, while SPY returned -2.8% and -0.2%, respectively. This indicates PEPG has been having a stronger performance recently.
PEPG support price is $4.70 and resistance is $5.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PEPG shares will trade within this expected range on the day.
